Veloxis Pharmaceuticals AS (VELO) – Strategy, SWOT and Corporate Finance Report
- Pages: 43
- Published: August 2020
- Report Code: MLPH61177FSA
Veloxis Pharmaceuticals AS (VELO) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company
Key Highlights
Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company lead product is ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients. ENVARSUS is developed based on the company’s proprietary, patented drug delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company sells ENVARSUS XR to government agencies, specialty pharmacies, managed healthcare organizations, wholesalers and retail customers across the US, Europe and worldwide. Veloxis is headquartered in Copenhagen, Denmark.
Scope
• Detailed information on Veloxis Pharmaceuticals AS required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Veloxis Pharmaceuticals AS in the form of a SWOT analysis
• An in-depth view of the business model of Veloxis Pharmaceuticals AS including a breakdown and examination of key business segments
• News about Veloxis Pharmaceuticals AS, such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
• Gain understanding of Veloxis Pharmaceuticals AS and the factors that influence its strategies.• Track strategic initiatives of the company and latest corporate news and actions.
• Assess Veloxis Pharmaceuticals AS as a prospective partner, vendor or supplier.
• Support sales activities by understanding your customers' businesses better.
• Stay up to date on Veloxis Pharmaceuticals ASs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
Sanofi-Aventis Canada Inc
Roche a/s
Quantum Genomics SA
Novartis Pharmaceuticals UK Ltd
Metkinen Oy
Genzyme Corp
Astellas Pharma A/S
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.